The race to block TNF-alpha: the caution flag is raised again.
Kaplan
Gil
G
Inflammatory Bowel Disease Center, University of Calgary, Alberta, Canada.
Panaccione
Remo
R
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001424:Bacterial Infections / Q000209:etiology*; D006801:Humans; D000069285:Infliximab; D012189:Retrospective Studies; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology*
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab